OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Interplay between platelets and coagulation	188
Targeting MCL-1 in hematologic malignancies: Rationale and progress	140
Coagulation and anticoagulation in COVID-19	140
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system	128
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes	114
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	104
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents	98
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	82
A review of FLT3 inhibitors in acute myeloid leukemia	77
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	71
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	70
The looming storm: Blood and cytokines in COVID-19	68
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	59
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	56
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation	53
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions	53
Current state and next-generation CAR-T cells in multiple myeloma	53
Illness and prognostic understanding in patients with hematologic malignancies	48
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	46
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies	43
Inherited thrombocytopenias: an updated guide for clinicians	43
Current and emerging strategies for management of myelodysplastic syndromes	40
Discussing investigational AAV gene therapy with hemophilia patients: A guide	40
Second primary malignancies in multiple myeloma: A review	38
Complement activation in COVID-19 and targeted therapeutic options: A scoping review	36

IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly	35
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	34
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	34
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	33
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation	31
CLL update 2022: A continuing evolution in care	28
Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management	28
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	28
Immune thrombocytopenia: A review of upfront treatment strategies	28
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management	28
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	28
It takes two to thrombosis: Hemolysis and complement	27
Metabolic regulation of the bone marrow microenvironment in leukemia	27
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	27
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	26
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?	26
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models	26
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	26
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	26
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions	26
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	26
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness	25
Determinants of severity in sickle cell disease	24
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	24
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	23
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?	23
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations	23
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways	23
Magnesium: The overlooked electrolyte in blood cancers?	22
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia	22
Artificial intelligence in hematological diagnostics: Game changer or gadget?	21
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap	21
A review on how to do hematology consults during COVID-19 pandemic	21
Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations	21
AML and the art of remission maintenance	20
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	20
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	20
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation	19
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity	19
Revisiting Richter transformation in the era of novel CLL agents	19
Targeting cereblon in hematologic malignancies	19
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics	18
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	18
Advances in the management of TTP	18
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?	18
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses	17
Health related quality of life in children with sickle cell disease: A systematic review and meta-analysis	17
Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses	17
The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types	17
Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies	17

Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization